

Part VI: Summary of the risk management plan

Summary of risk management plan for Procoralan[®], Corlentor[®], Ivabradine Anpharm and Ivabradine Biogaran (Ivabradine hydrochloride)

This is a summary of the risk management plan (RMP) for Procoralan[®], Corlentor[®], Ivabradine Anpharm and Ivabradine Biogaran. The RMP details important risks of these products, how these risks can be minimised, and how more information will be obtained about these products' risks and uncertainties (missing information).

These products' summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how these products should be used.

This summary of the RMP for these products should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of these products' RMP.

I. The medicine and what it is used for

Procoralan[®], Corlentor[®], Ivabradine Anpharm and Ivabradine Biogaran, are authorised for symptomatic treatment of chronic stable angina pectoris and treatment of chronic heart failure (see SmPC for the full indication). These products contain ivabradine as the active substance and are taken orally twice daily.

Further information about the evaluation of benefits can be found in EPAR, including in its plain-language summary, available on the EMA website, under the medicine's webpage:

- For Procoralan: <https://www.ema.europa.eu/en/medicines/human/EPAR/procoralan>
- For Corlentor: <https://www.ema.europa.eu/en/medicines/human/EPAR/corlentor>
- For Ivabradine Anpharm: <https://www.ema.europa.eu/en/medicines/human/EPAR/ivabradine-anpharm>

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Procoralan[®], Corlentor[®], Ivabradine Anpharm and Ivabradine Biogaran, together with measures to minimise such risks and the proposed studies for learning more about these products' risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PBREER assessment so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A List of important risks and missing information

Important risks of Procoralan[®], Corlentor[®], Ivabradine Anpharm and Ivabradine Biogaran are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of these products. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	None
Important potential risks	None
Missing information	None

II.B Summary of important risks

Not applicable.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Procoralan[®], Corlentor[®], Ivabradine Anpharm and Ivabradine Biogaran.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Procoralan[®], Corlentor[®], Ivabradine Anpharm and Ivabradine Biogaran.